Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 10, 2010, Pages 3116-3119

  Rotstein, David M ^a   Melville, Chris R ^a   Padilla, Fernando ^a   Cournoyer, Dick ^a   Lee, Eun K ^a   Lemoine, Remy ^a   Petersen, Ann C ^a   Setti, Lina Q ^a   Wanner, Jutta ^a   Chen, Lijing ^a   Filonova, Lubov ^a   Loughhead, David G ^a   Manka, Jason ^a   Lin, Xiao Fa ^a   Gleason, Shelley ^a   Sankuratri, Surya ^a   Ji, Changhua ^a   deRosier, Andre ^a   Dioszegi, Marianna ^a   Heilek, Gabrielle ^a   Jekle, Andreas ^a   Berry, Pamela ^a   Mau, Cheng I ^a   Weller, Paul ^a   more..

^a ROCHE BIOSCIENCE   (United States)

Author keywords

Anti HIV 1; Antiviral; CCR5 antagonist; Chemokine

Indexed keywords

CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HEXAHYDROPYRROLO[3,4]PYRROLE; MARAVIROC; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-HIV AGENTS; BENZAMIDES; HIV FUSION INHIBITORS; HUMANS; MICROSOMES, LIVER; PYRROLES; RATS; RECEPTORS, CCR5; STRUCTURE-ACTIVITY RELATIONSHIP;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77952099769     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.095     Document Type: Article

References (11)

1. Perno C.-F., Moyle G., Tsoukas C., Ratanasuwan W., Gatell J., and Schechter M. J. Med. Virol. 80 (2008) 565
2. Palani A., and Tagat J.R. J. Med. Chem. 49 (2006) 2851
3. Rotstein D.M., Gabriel S.D., Makra F., Filonova F., Gleason S., Brotherton-Pleiss C., Setti L.Q., Trejo-Martin A., Lee E.K., Sankuratri S., Ji C., de Rosier A., Dioszegi M., Heilek G., Jekle A., Berry P., Weller P., and Mau C.-I. Bioorg. Med. Chem. Lett. 19 (2009) 5401
4. Turner J.E., Steinmetz O.M., Stahl R.A., and Panzer U. Mini-Rev. Med. Chem. 7 (2007) 1089
5. MacArthur R.D., and Novak R.M. Rev. Anti-Infect. Agents 47 (2008) 236
6. Palani A., Shapiro S., Clader J.W., Greenlee W.J., Cox K., Strizki J., Endres M., and Baroudy B.M. J. Med. Chem. 44 (2001) 3339
7. Briefly, for the antiviral assay, pseudo-type particles were generated by co-transfection of envelope deleted HIV-1 genomic plasmid (derived from pNL4-3) and an envelope expression plasmid carrying viral envelope from NL-Bal into 293T cells. Culture supernatant containing pseudo-typed viruses was harvested after 2 days and used to infect JC53-BL reporter cells. Luciferase reporter gene activity was measured 3 days post-infection. For more detailed assay protocols see: Melville, C.R.; Rotstein, D.M. WO2008119663.
8. The thresholds above which intrinsic mircrosomal clearance values were considered to be high were ≥90 μl/min/mL for RLM and ≥35 μl/min/ml for HLM. These scaled to in vivo clearance values ≥70% of liver blood flow using the well-stirred model. Intrinsic microsomal clearance values corresponding to ≤30% of liver blood flow (≤15 μl/min/ml for RLM and ≤6.5 μl/min/ml for HLM) were considered to be low.
9. Obach R.S. Curr. Opin. Drug Discovery Dev. 4 (2001) 36
10. Ernst J., Dahl R., Lum C., Urban J., Miller S.G., and Lundström. J. Bioorg. Med. Chem. Lett. 18 (2008) 1498
11. For more detailed experimental information, see: Lee, E.K.; Melville, C. R.; Rotstein, D.M. WO2005121145.